elevationoncology.com (ELEV): Price-to-Revenue Ratio

Symbol and logo of brand elevationoncology.com (ELEV)

The P/S ratio history of Elevation Oncology (ELEV) reflects the market value dynamics of a company developing unique antibodies to combat specific genetic mutations. captures the magnitude of this parameter. The brand relies on the precision of genetic analysis when developing drugs for rare tumors and is implementing automated systems to analyze large clinical datasets.

ELEV elevationoncology.com Market Cap to Revenue (07/04/2022 - 11/13/2026)

Elevation Oncology (ELEV) - metric breakdowns and financial figures

- current quotes and average value forecast:
Market Price Elevation Oncology Inc.|ELEV - Price Target Chart
- stock exchange capitalization data:
Market Value Elevation Oncology|ELEV - Enterprise Value
- issuer book value statistics:
Net Asset Value per Share Elevation Oncology|ELEV - Company Net Assets|Market Value to Book Value Ratio elevationoncology.com|ELEV - Company Total Assets
- debt obligations and liquidity statistics:
Total Debt to Capital Elevation Oncology|ELEV - Long-Term Debt to Equity Ratio|Short-Term Loans to Capital Ratio elevationoncology.com|ELEV - Company Aggregate Debts|Debts to Net Assets Elevation Oncology|ELEV - Company Long-Term Debt|Short-Term Debt Elevation Oncology|Immediate Liquidity Ratio elevationoncology.com
- earnings and multiples data:
ELEV - Net Income|Expected Net Income Elevation Oncology|ELEV - Price to Earnings Ratio|Projected Price to Earnings Ratio Elevation Oncology Inc.|ELEV - Price/Earnings to Growth Ratio|Enterprise Value to Operating Income Before Depreciation Elevation Oncology|ELEV - Operating profit EBITDA|Net earnings per share for the last 12 months Elevation Oncology|ELEV - Earnings per share for the last twelve months|Earnings per share growth in annualized terms for the last twelve months elevationoncology.com|ELEV - Earnings per share growth in current year|Net earnings per share growth forecast for next year Elevation Oncology
- sales revenue and business income indicators:
ELEV - Company Revenue|Company Expected Sales Volume elevationoncology.com|ELEV - P/S Multiple|Projected Price to Revenue Elevation Oncology
General company analysis:ELEV, Elevation Oncology Inc.
Signature product of Elevation Oncology Inc.

A conservative approach to analyzing Elevation Oncology (ELEV) requires comparing market capitalization with annual sales volume to identify asset overvaluation. By analyzing current P/S dynamics, an investor assesses the cost per unit of revenue, which, in the context of inelastic demand for the unique EO-3021 conjugate, confirms the company's strong pricing power and the potential for growth in its investment profile.

Competitors of Elevation Oncology

ONC - Price to Sales|Price-to-Revenue Ratio Halozyme HALO|Revolution Medicines Inc - Price-to-Revenue Ratio|Ascentage - P/S Multiple|Price to Sales CG Oncology Therapeutics|URGN (UroGen Pharma Ltd.) - Market Cap to Revenue|BCAX (bicara.com) - Price-to-Revenue Ratio|PSNL (Personalis) - P/S Multiple|P/S Multiple Erasca Inc|Market Cap to Revenue DCTH (Delcath)|Market Cap to Sales Volume YMAB|P/S Multiple AURA (Aura Biosciences, Inc.)|Price-to-Revenue Coefficient Candel Therapeutics Inc. (CADL)|ARAY - Price-to-Revenue Ratio|Price to Sales SELLAS Life Sciences|Actuate Therapeutics, Inc (ACTU) - Price-to-Revenue Ratio|Market Cap to Revenue Ratio CTOR|Market Cap to Revenue HURA|TARA: Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio Fate Therapeutics (FATE)|WHWK - Price to Sales|Price-to-Revenue Ratio TScan Therapeutics, Inc. TCRX|CSBR: Market Cap to Revenue Ratio|XBiotech USA - P/S Multiple|CEL-SCI Corporation (CVM) - Market Cap to Revenue|OS Therapies (OSTX) - Price-to-Revenue Ratio|Price to Sales radiopharmtheranostics.com (RADX)|Price-to-Revenue Ratio Artiva Biotherapeutics Inc.|Price-to-Revenue Ratio ANL|Price-to-Revenue Ratio Veru Inc. (VERU)|TPST - Price to Sales|P/S Multiple XLO (Xilio Therapeutics)|Price-to-Revenue Multiple Renovaro Biosciences|MURA: Market Cap to Revenue|Price to Sales Kairos Pharma Ltd|OKUR: P/S Multiple|Price to Sales CytoMed Therapeutics Limited (GDTC)|Price-to-Revenue Ratio Curis Inc.|Price-to-Revenue Ratio APLM|P/S Multiple THAR|ADVB - Price to Sales|Genprex, Inc. - Market Cap to Revenue|Calidi Biotherapeutics Inc. - Price-to-Revenue Ratio|Sunshine Biopharma, Inc. - P/S Multiple|Xenetic Biosciences (XBIO) - Market Cap to Revenue|SLRX: P/S Multiple|Kitov Pharma (PPBT) - P/S Multiple|Price-to-Revenue Ratio American Oncology Network Inc|Market Cap to Revenue Ratio BGNE (beigene.com)|P/S Multiple CKPT|Market Cap to Revenue icadmed.com ICAD|P/S Multiple IKNA (Ikena Oncology)|Notable Labs Corp (NTBL) - Price to Sales|VIRX - Price-to-Revenue Ratio|Market Capitalization-to-Revenue Ratio MOR (morphosys.com)|NAYA (NAYA Biosciences Inc.) - Market Cap to Revenue|Ascentage Pharma Group International - Market Capitalization-to-Revenue Ratio